CapAI Signs License, Option Deal for R42 Group's AI Health Data Platform

MT Newswires · 2d ago
06:57 AM EDT, 07/23/2026 (MT Newswires) -- CapAI (CPAI.L) signed a license and option agreement for R42 Group's artificial intelligence-powered longevity and preventative health data platform Ageotype. The London-listed applied AI venture platform was granted an exclusive worldwide license to develop and commercialize Ageotype for 12 months to July 22, 2027, according to a Thursday filing. CapAI also has a discretionary option to acquire the associated intellectual property for 2 million pounds sterling. Should the company exercise this option, R42 would be entitled to 20% of net proceeds from any future monetization of the underlying IP.